Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy

• Status: Unknown status
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years duration and a second research kidney biopsy, could enter the double blind treatment study of Atacand or Placebo.

The treatment study continues for five years treatment and ends with a third kidney biopsy.

The study hypothesis is that the effect of ARB during 5 years on the histopathology are more pronounced than the effect on histopathology of placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska University Hospital
• Collaborator: AstraZeneca
• Treatments: Candesartan

Criteria

Inclusion Criteria:

• Diabetes type 1 patient

• Normotensive

• Normoalbuminuric

• Signed informed consent

• Female and male

• Over 17 years of age

• Diabetes duration over 10 years

Exclusion Criteria:

• Hypertension

• Microalbuminuria

• Pregnancy

• Lactation

• Reduced kidney function

• Artery stenosis

• Kidney transplantation

• Allergy to the medication in the study

• Reduced liver function

• Alcohol or drug abuse

• Participation in another drug or clinical test during last 30 days

• Severe diseases i.e. malignancy

• Previously enrolment of the present study